ES2609847T3 - Vacunas de herpesvirus basadas en vectores del virus de la enfermedad de Newcastle - Google Patents
Vacunas de herpesvirus basadas en vectores del virus de la enfermedad de Newcastle Download PDFInfo
- Publication number
- ES2609847T3 ES2609847T3 ES11752432.2T ES11752432T ES2609847T3 ES 2609847 T3 ES2609847 T3 ES 2609847T3 ES 11752432 T ES11752432 T ES 11752432T ES 2609847 T3 ES2609847 T3 ES 2609847T3
- Authority
- ES
- Spain
- Prior art keywords
- herpesvirus
- composition
- ndv
- recombinant
- disease virus
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/155—Paramyxoviridae, e.g. parainfluenza virus
- A61K39/17—Newcastle disease virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/245—Herpetoviridae, e.g. herpes simplex virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5256—Virus expressing foreign proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
- A61K2039/552—Veterinary vaccine
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/16011—Herpesviridae
- C12N2710/16711—Varicellovirus, e.g. human herpesvirus 3, Varicella Zoster, pseudorabies
- C12N2710/16722—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/16011—Herpesviridae
- C12N2710/16711—Varicellovirus, e.g. human herpesvirus 3, Varicella Zoster, pseudorabies
- C12N2710/16734—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/18011—Paramyxoviridae
- C12N2760/18111—Avulavirus, e.g. Newcastle disease virus
- C12N2760/18134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/18011—Paramyxoviridae
- C12N2760/18111—Avulavirus, e.g. Newcastle disease virus
- C12N2760/18141—Use of virus, viral particle or viral elements as a vector
- C12N2760/18143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/18011—Paramyxoviridae
- C12N2760/18111—Avulavirus, e.g. Newcastle disease virus
- C12N2760/18151—Methods of production or purification of viral material
- C12N2760/18152—Methods of production or purification of viral material relating to complementing cells and packaging systems for producing virus or viral particles
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Virology (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- Zoology (AREA)
- Microbiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- Biomedical Technology (AREA)
- General Engineering & Computer Science (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Plant Pathology (AREA)
- Gastroenterology & Hepatology (AREA)
- Physics & Mathematics (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Pulmonology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
Una composición o vacuna que comprende (i) uno o más vectores de virus de la enfermedad de Newcastle (NDV)-herpesvirus recombinantes, y (ii) un vehículo aceptable en farmacia o veterinaria; en la que la composición o vacuna comprende dos vectores de NDV-herpesvirus recombinantes, en la que la composición o vacuna comprende un primer vector de NDV-herpesvirus recombinante que comprende un polinucleótido que codifica un antígeno gB de herpesvirus felino y un segundo vector de NDV-herpesvirus recombinante que comprende un polinucleótido que codifica un antígeno gD de herpesvirus felino, o en la que la composición o vacuna comprende un vector de NDV-herpesvirus recombinante, en la que la composición o vacuna comprende un vector de NDV-herpesvirus recombinante que comprende una combinación de un polinucleótido que codifica un antígeno gB de herpesvirus felino y un polinucleótido que codifica un antígeno gD de herpesvirus felino.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US37857510P | 2010-08-31 | 2010-08-31 | |
US378575P | 2010-08-31 | ||
PCT/US2011/049554 WO2012030720A1 (en) | 2010-08-31 | 2011-08-29 | Newcastle disease virus vectored herpesvirus vaccines |
Publications (1)
Publication Number | Publication Date |
---|---|
ES2609847T3 true ES2609847T3 (es) | 2017-04-24 |
Family
ID=44736033
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ES11752432.2T Active ES2609847T3 (es) | 2010-08-31 | 2011-08-29 | Vacunas de herpesvirus basadas en vectores del virus de la enfermedad de Newcastle |
Country Status (10)
Country | Link |
---|---|
US (2) | US8986706B2 (es) |
EP (3) | EP4014989A1 (es) |
JP (1) | JP5913316B2 (es) |
CN (1) | CN103269714B (es) |
BR (1) | BR112013007486B1 (es) |
CA (1) | CA2809127C (es) |
ES (1) | ES2609847T3 (es) |
MX (1) | MX344103B (es) |
PL (1) | PL2611460T3 (es) |
WO (1) | WO2012030720A1 (es) |
Families Citing this family (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9635540B2 (en) | 2002-03-25 | 2017-04-25 | Jeffrey D. Mullen | Systems and methods for locating cellular phones and security measures for the same |
CN103585643A (zh) * | 2009-04-03 | 2014-02-19 | 梅里亚有限公司 | 运载新城疫病毒的禽疫苗 |
RU2593950C2 (ru) | 2011-10-21 | 2016-08-10 | Интервет Интернэшнл Б.В. | Рекомбинантный непатогенный mdv-вектор, обеспечивающий полиспецифический иммунитет |
US8932604B2 (en) | 2011-10-21 | 2015-01-13 | Intervet Inc. | Recombinant non-pathogenic marek's disease virus constructs encoding infectious laryngotracheitis virus and newcastle disease virus antigens |
WO2013142371A1 (en) | 2012-03-20 | 2013-09-26 | Merial Limited | Recombinant equine herpesvirus-1 vaccine containing mutated glycoprotein c and uses thereof |
EP2873728A1 (en) * | 2013-11-18 | 2015-05-20 | Institut Pasteur | A subunit vaccine platform based on multimeric ribonucleoproteins comprising nucleoproteins of a non-segmented negative-strand RNA virus as carriers of heterologous polypeptides |
WO2015130492A1 (en) | 2014-02-25 | 2015-09-03 | The United States Of America, As Represented By The Secretary Of Agriculture | Novel immunogenic composition |
CN104988124B (zh) * | 2015-05-07 | 2018-05-22 | 中国农业科学院兰州兽医研究所 | 基因ⅶ型新城疫病毒标记疫苗株及其应用 |
US10196616B2 (en) | 2017-02-15 | 2019-02-05 | The United States Of America, As Represented By The Secretary Of Agriculture | Altered avian virus for in-ovo inoculation and methods of use thereof |
CN109679970B (zh) * | 2018-11-20 | 2020-12-08 | 杭州贤至生物科技有限公司 | 猫疱疹i型病毒快速检测的制备方法 |
EP4243866A1 (en) * | 2020-11-13 | 2023-09-20 | Boehringer Ingelheim Vetmedica GmbH | New feline herpes virus vaccine |
CN113943354B (zh) * | 2021-10-11 | 2022-09-06 | 中国农业科学院上海兽医研究所(中国动物卫生与流行病学中心上海分中心) | 一种重组猫疱疹病毒gB蛋白抗原及其在抗体诊断和疫苗制备中的应用 |
CN116121282B (zh) * | 2023-01-10 | 2023-09-22 | 浙江大学 | 一种表达猫疱疹病毒蛋白的mRNA疫苗及其制备方法 |
CN116497049B (zh) * | 2023-05-04 | 2024-03-22 | 江苏三仪生物工程有限公司 | 一种表达犬疱疹病毒gD糖基化蛋白的重组菌及其应用 |
Family Cites Families (80)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2909462A (en) | 1955-12-08 | 1959-10-20 | Bristol Myers Co | Acrylic acid polymer laxative compositions |
US4394448A (en) | 1978-02-24 | 1983-07-19 | Szoka Jr Francis C | Method of inserting DNA into living cells |
US4769331A (en) | 1981-09-16 | 1988-09-06 | University Patents, Inc. | Recombinant methods and materials |
US5505941A (en) | 1981-12-24 | 1996-04-09 | Health Research, Inc. | Recombinant avipox virus and method to induce an immune response |
US4722848A (en) | 1982-12-08 | 1988-02-02 | Health Research, Incorporated | Method for immunizing animals with synthetically modified vaccinia virus |
US4603112A (en) | 1981-12-24 | 1986-07-29 | Health Research, Incorporated | Modified vaccinia virus |
US5833975A (en) | 1989-03-08 | 1998-11-10 | Virogenetics Corporation | Canarypox virus expressing cytokine and/or tumor-associated antigen DNA sequence |
US4769330A (en) | 1981-12-24 | 1988-09-06 | Health Research, Incorporated | Modified vaccinia virus and methods for making and using the same |
US5338683A (en) * | 1981-12-24 | 1994-08-16 | Health Research Incorporated | Vaccinia virus containing DNA sequences encoding herpesvirus glycoproteins |
US5174993A (en) | 1981-12-24 | 1992-12-29 | Health Research Inc. | Recombinant avipox virus and immunological use thereof |
JPS60500673A (ja) | 1983-03-08 | 1985-05-09 | コモンウエルス セラム ラボラトリ−ズ コミツシヨン | 抗原活性を有するアミノ酸配列 |
US4745051A (en) | 1983-05-27 | 1988-05-17 | The Texas A&M University System | Method for producing a recombinant baculovirus expression vector |
EP0173552B1 (en) | 1984-08-24 | 1991-10-09 | The Upjohn Company | Recombinant dna compounds and the expression of polypeptides such as tpa |
US4945050A (en) | 1984-11-13 | 1990-07-31 | Cornell Research Foundation, Inc. | Method for transporting substances into living cells and tissues and apparatus therefor |
US5168062A (en) | 1985-01-30 | 1992-12-01 | University Of Iowa Research Foundation | Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence |
US4968615A (en) | 1985-12-18 | 1990-11-06 | Ciba-Geigy Corporation | Deoxyribonucleic acid segment from a virus |
US4963481A (en) | 1985-12-18 | 1990-10-16 | Genetics Institute Inc | Promoter system |
DK175363B1 (da) | 1986-09-12 | 2004-09-13 | Genentech Inc | Fremgangsmåde til kontinuert produktion af et önsket heterologt protein i en eukaryotisk værtcelle, vektor, som tilförer denne evne, og celler transformeret med vektoren |
IE872748L (en) | 1986-10-16 | 1988-04-16 | Arjomari Europ | Polypeptides derived from the evvelope gene of human¹immunodeficiency virus in recombinant baculovirus infected¹insect cells |
GB8717430D0 (en) | 1987-07-23 | 1987-08-26 | Celltech Ltd | Recombinant dna product |
DE3743138A1 (de) | 1987-12-18 | 1989-09-14 | Mayr Christian Gmbh & Co Kg | Schleifringlose, elektromagnetische ueberlastkupplung |
WO1990001543A1 (fr) | 1988-07-29 | 1990-02-22 | Intracel Corporation | Procede d'expression genetique de proteines heterologues par des cellules transfectees in vivo |
CA2003300A1 (en) | 1988-11-21 | 1990-05-21 | Franklin Volvovitz | Skin test and test kit for aids |
US5703055A (en) | 1989-03-21 | 1997-12-30 | Wisconsin Alumni Research Foundation | Generation of antibodies through lipid mediated DNA delivery |
US5552143A (en) | 1989-03-24 | 1996-09-03 | The Wistar Institute Of Anatomy & Biology | Recombinant cytomegalovirus vaccine |
US5591439A (en) | 1989-03-24 | 1997-01-07 | The Wistar Institute Of Anatomy And Biology | Recombinant cytomegalovirus vaccine |
US5118502A (en) | 1989-06-20 | 1992-06-02 | The University Of Georgia Research Foundation, Inc. | Naturally attenuated newcastle disease vaccine and method of using the same |
GB9001766D0 (en) | 1990-01-25 | 1990-03-28 | Univ Court Of The University O | Vaccines |
US5514375A (en) | 1990-08-15 | 1996-05-07 | Virogenetics Corporation | Flavivirus recombinant poxvirus vaccine |
MY109299A (en) | 1990-08-15 | 1996-12-31 | Virogenetics Corp | Recombinant pox virus encoding flaviviral structural proteins |
US5863542A (en) | 1991-03-07 | 1999-01-26 | Virogenetics Corporation | Recombinant attenuated ALVAC canaryopox virus containing heterologous HIV or SIV inserts |
KR100242671B1 (ko) | 1991-03-07 | 2000-03-02 | 고돈 에릭 | 유전학적으로 처리한 백신 균주 |
US5997878A (en) | 1991-03-07 | 1999-12-07 | Connaught Laboratories | Recombinant poxvirus-cytomegalovirus, compositions and uses |
US5801029A (en) | 1993-02-16 | 1998-09-01 | Onyx Pharmaceuticals, Inc. | Cytopathic viruses for therapy and prophylaxis of neoplasia |
US6010703A (en) * | 1993-07-26 | 2000-01-04 | Board Of Trustees Operating Michigan State University | Recombinant poxvirus vaccine against feline rhinotracheitis |
US6485729B1 (en) | 1993-09-13 | 2002-11-26 | Protein Sciences Corporation | Neuraminidase-supplemented compositions |
JP3745370B2 (ja) * | 1994-03-30 | 2006-02-15 | ヴァイロジェネティクス コーポレイション | イヌヘルペスウイルスgB、gCおよびgDの、核酸およびアミノ酸配列とその利用 |
WO1996013575A1 (en) * | 1994-10-26 | 1996-05-09 | Syntro Corporation | Recombinant feline herpes virus |
FR2728795B1 (fr) | 1994-12-30 | 1997-03-21 | Rhone Merieux | Vaccin vivant recombinant aviaire, utilisant comme vecteur un virus herpes aviaire |
JPH11504631A (ja) | 1995-04-25 | 1999-04-27 | バイカル インコーポレイテッド | Dna/脂質複合体の単一バイアル製剤 |
US5733556A (en) * | 1995-10-18 | 1998-03-31 | Akzo Nobel N.V. | Newcastle disease virus combination vaccine |
FR2741806B1 (fr) | 1995-11-30 | 1998-02-20 | Rhone Merieux | Vaccin vivant recombinant a base d'herpesvirus felin de type 1, notamment contre la peritonite infectieuse feline |
FR2750865B1 (fr) | 1996-06-27 | 1998-12-04 | Rhone Merieux | Vaccin vivant recombinant a base d'herpesvirus canin, notamment contre la maladie de carre, la rage ou le virus parainfluenza de type 2 |
FR2750866B1 (fr) | 1996-06-27 | 1998-11-27 | Rhone Merieux | Vaccin vivant recombinant aviaire, utilisant comme vecteur le virus de la laryngotracheite infectieuse aviaire |
US6156567A (en) | 1996-07-03 | 2000-12-05 | Merial | Truncated transcriptionally active cytomegalovirus promoters |
US6090393A (en) | 1996-07-03 | 2000-07-18 | Merial | Recombinant canine adenoviruses, method for making and uses thereof |
JP2002512501A (ja) | 1996-07-03 | 2002-04-23 | メリアル インコーポレイテッド | 外来性dnaを含む組換えイヌアデノウィルス(cav) |
FR2751228B1 (fr) | 1996-07-19 | 1998-11-20 | Rhone Merieux | Vaccin polynucleotidique bovin pour voie intradermique |
FR2751223B1 (fr) | 1996-07-19 | 1998-12-04 | Rhone Merieux | Formule de vaccin polynucleotidique felin |
FR2751225B1 (fr) | 1996-07-19 | 1998-11-27 | Rhone Merieux | Formule de vaccin polynucleotidique aviaire |
FR2751224B1 (fr) | 1996-07-19 | 1998-11-20 | Rhone Merieux | Formule de vaccin polynucleotidique contre les pathologies respiratoires et de reproduction des porcs |
FR2751227B1 (fr) | 1996-07-19 | 1998-11-27 | Rhone Merieux | Formule de vaccin polynucleotidique contre les pathologies canines, notamment les pathologies respiratoires et digestives |
FR2751229B1 (fr) | 1996-07-19 | 1998-11-27 | Rhone Merieux | Formule de vaccin polynucleotidique notamment contre la pathologie respiratoire des bovins |
FR2751226B1 (fr) | 1996-07-19 | 1998-11-27 | Rhone Merieux | Formule de vaccin polynucleotidique contre les pathologies du cheval |
EP1537877A3 (en) | 1996-10-11 | 2005-08-03 | The Regents Of The University Of California | Immunostimulatory polynucleotide/immunomodulatory molecule conjugates |
ES2153654T3 (es) | 1996-10-17 | 2001-03-01 | Oxford Biomedica Ltd | Vectores retrovirales. |
FR2757061B1 (fr) | 1996-12-16 | 1999-03-26 | Rhone Merieux | Vaccin vivant recombinant aviaire, utilisant comme vecteur le virus de la laryngotracheite infectieuse aviaire |
FR2758986B1 (fr) | 1997-01-31 | 1999-04-30 | Rhone Merieux | Vaccin vivant recombinant aviaire, utilisant comme vecteur le virus de la laryngotracheite infectieuse aviaire |
US6183752B1 (en) | 1997-02-05 | 2001-02-06 | Pasteur Merieux Serums Et Vaccins | Restenosis/atherosclerosis diagnosis, prophylaxis and therapy |
US6368603B1 (en) | 1997-03-05 | 2002-04-09 | Merial Limited | Lyme combination compositions and uses |
US5990091A (en) | 1997-03-12 | 1999-11-23 | Virogenetics Corporation | Vectors having enhanced expression, and methods of making and uses thereof |
US6004777A (en) | 1997-03-12 | 1999-12-21 | Virogenetics Corporation | Vectors having enhanced expression, and methods of making and uses thereof |
US6410311B1 (en) * | 1997-05-09 | 2002-06-25 | Schering-Plough Veterinary Corporation | Recombinant feline herpesvirus comprising a foreign DNA inserted into a region corresponding to a 3.0 kb EcoRI-SalI fragment of a feline herpesvirus genome |
US6348450B1 (en) | 1997-08-13 | 2002-02-19 | The Uab Research Foundation | Noninvasive genetic immunization, expression products therefrom and uses thereof |
US6391314B1 (en) | 1997-10-03 | 2002-05-21 | Merial | Porcine circoviruses vaccines diagnostic reagents |
FR2781159B1 (fr) | 1998-07-06 | 2000-10-06 | Merial Sas | Vaccin circovirus et parvovirus porcin |
US6224882B1 (en) | 1997-11-07 | 2001-05-01 | Protein Science Corp. | Insect cells or fractions as adjuvant for antigens |
CN1322137C (zh) | 1997-12-22 | 2007-06-20 | 牛津生物医学(英国)有限公司 | 基于马传染性贫血病毒(eiav)的逆转录病毒载体 |
FR2778858B1 (fr) | 1998-05-20 | 2000-06-16 | Oreal | Emulsion e/h/e stable et son utilisation comme composition cosmetique et/ou dermatologique |
US6146642A (en) * | 1998-09-14 | 2000-11-14 | Mount Sinai School Of Medicine, Of The City University Of New York | Recombinant new castle disease virus RNA expression systems and vaccines |
US6103526A (en) | 1998-10-08 | 2000-08-15 | Protein Sciences Corporation | Spodoptera frugiperda single cell suspension cell line in serum-free media, methods of producing and using |
US6497883B1 (en) | 1999-06-10 | 2002-12-24 | Merial | Porcine circovirus recombinant poxvirus vaccine |
FR2801607B1 (fr) | 1999-11-26 | 2001-12-28 | Merial Sas | Pneumovirus du canard et vaccins correspondants |
CA2399202A1 (en) * | 2000-03-09 | 2001-09-13 | Heska Corporation | Use of recombinant antigens to determine the immune status of an animal |
CA2533581C (en) | 2003-07-24 | 2012-05-08 | Merial Limited | Vaccine formulations comprising an oil-in-water emulsion |
DE602006019878D1 (de) * | 2005-07-28 | 2011-03-10 | Pfizer Prod Inc | Impfstoff gegen felines calicivirus (fcv), der ein fcv kapsid protein oder ein isoliertes fcv kapsid protein mit der protein sequenz seq id no: 13 oder mit einer protein sequenz, die zumindestens zu 95% identisch zur seq id no: 13 ist enthält. |
JP2009529861A (ja) * | 2006-03-15 | 2009-08-27 | インターベツト・インターナシヨナル・ベー・ベー | 鳥インフルエンザウイルスのh5ヘマグルチニンを発現する組み換えニューキャッスル病ウイルス |
KR20100038323A (ko) * | 2007-05-30 | 2010-04-14 | 와이어쓰 엘엘씨 | 고양이 항원의 유전자를 발현하는 라쿤 폭스바이러스 |
WO2009051823A2 (en) * | 2007-10-18 | 2009-04-23 | Michigan State University | Bacterial artificial chromosome containing feline herpes virus type 1 genome and uses thereof |
CN103585643A (zh) | 2009-04-03 | 2014-02-19 | 梅里亚有限公司 | 运载新城疫病毒的禽疫苗 |
-
2011
- 2011-08-29 WO PCT/US2011/049554 patent/WO2012030720A1/en active Application Filing
- 2011-08-29 ES ES11752432.2T patent/ES2609847T3/es active Active
- 2011-08-29 EP EP21209670.5A patent/EP4014989A1/en not_active Withdrawn
- 2011-08-29 BR BR112013007486A patent/BR112013007486B1/pt active IP Right Grant
- 2011-08-29 MX MX2013002181A patent/MX344103B/es active IP Right Grant
- 2011-08-29 JP JP2013527164A patent/JP5913316B2/ja active Active
- 2011-08-29 EP EP16181806.7A patent/EP3156070A3/en not_active Withdrawn
- 2011-08-29 EP EP11752432.2A patent/EP2611460B1/en active Active
- 2011-08-29 PL PL11752432T patent/PL2611460T3/pl unknown
- 2011-08-29 US US13/220,196 patent/US8986706B2/en active Active
- 2011-08-29 CN CN201180049074.9A patent/CN103269714B/zh active Active
- 2011-08-29 CA CA2809127A patent/CA2809127C/en active Active
-
2015
- 2015-02-06 US US14/616,011 patent/US9446118B2/en active Active
Also Published As
Publication number | Publication date |
---|---|
BR112013007486B1 (pt) | 2020-01-28 |
WO2012030720A1 (en) | 2012-03-08 |
US20150157704A1 (en) | 2015-06-11 |
CA2809127C (en) | 2019-04-02 |
US9446118B2 (en) | 2016-09-20 |
CA2809127A1 (en) | 2012-03-08 |
EP4014989A1 (en) | 2022-06-22 |
EP2611460B1 (en) | 2016-10-05 |
CN103269714B (zh) | 2016-06-29 |
CN103269714A (zh) | 2013-08-28 |
EP3156070A3 (en) | 2017-06-14 |
MX344103B (es) | 2016-12-05 |
US8986706B2 (en) | 2015-03-24 |
JP2013536847A (ja) | 2013-09-26 |
JP5913316B2 (ja) | 2016-04-27 |
US20120052089A1 (en) | 2012-03-01 |
EP2611460A1 (en) | 2013-07-10 |
EP3156070A2 (en) | 2017-04-19 |
MX2013002181A (es) | 2014-01-24 |
BR112013007486A2 (pt) | 2018-05-02 |
PL2611460T3 (pl) | 2017-02-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ES2609847T3 (es) | Vacunas de herpesvirus basadas en vectores del virus de la enfermedad de Newcastle | |
CY1120489T1 (el) | Εμβολια για hsv-2 | |
ES2723273T3 (es) | Vectores poxvirales recombinantes que expresan proteínas de la rabia y OX40 y vacunas fabricadas a partir de los mismos | |
CO7111302A2 (es) | Antígenos asociados a próstata y regímenes de inmunoterapia basados en vacuna | |
WO2010115133A3 (en) | Newcastle disease virus vectored avian vaccines | |
EA201390866A1 (ru) | Филовирусные вакцины на основе аденовирусов серотипа 26 и серотипа 35 | |
CO7160021A2 (es) | Virus del herpes aviar recombinantes multivalentes y vacunas para inmunizar especies aviares | |
MY173856A (en) | Recombinant non-pathogenic marek's disease virus constructs encoding infectious laryngotracheitis virus and newcastle disease virus antigens | |
MX340830B (es) | Vacuna neumococica y usos de la misma. | |
EA200700849A1 (ru) | Первичная/бустерная противомалярийная вакцина | |
PH12014502534A1 (en) | Effective vaccination against porcine reproductive and respiratory syndrome (prrs) virus prior to weaning | |
MX2013010620A (es) | Adenovirus de aves del serotipo 4 (fadv-4) no patogénico y vector viral del mismo. | |
WO2015134368A3 (en) | Recombinant herpes simplex virus 2 (hsv-2) vaccine vectors | |
MY173789A (en) | North american porcine reproductive and respiratory syndrome (prrs) virus and uses thereof | |
BRPI0816134A2 (pt) | Herpesvírus, sequência de dna, vetor, célula, vírus, método para produção de partículas infecciosas, partículas infecciosas, vacina, uso de herpesvírus ou da sequência de dna ou do vetor ou das partículas infecciosas, e, método para o tratamento preventivo e/ou terapêutico de uma doença. | |
CL2013001877A1 (es) | Composicion inmunogenica que comprende un virus de diarrea viral bovina tipo 1b vivo modificado y un portador veterinario aceptable; vacuna que la comprende; y su uso para prevenir, tratar, manejar o aliviar uno o mas sintomas de una enfermedad causada por pestivirus. | |
BR112018075513A2 (pt) | ácidos nucleicos que codificam as partículas seme-lhantes ao vírus da zika e seu uso nas vacinas e no ensaio de diagnóstico do vírus da zika | |
CL2012002900A1 (es) | Secuencias de acido nucleico procedente de un virus causante del sindrome de miocardiopatia (cms) en peces; vector; celula huesped; vacuna de adn; proteina recombinante codificada; vacuna recombinante; inmunoensayo para la deteccion de dicho virus; kit de diagnostico; y uso de las mismas. | |
AR101468A1 (es) | Vacuna en vector recombinante de adenovirus aviar serotipo 9 | |
WO2013001285A3 (en) | Fmdv vp1 peptides | |
AR094810A1 (es) | Parvovirus porcino 5b, métodos de uso y vacuna | |
CO6670515A2 (es) | Vectores de parapoxvirus | |
UY33523A (es) | ?vectores de parapoxvirus?. | |
MX2020004833A (es) | Un poliepitopo quimerico del virus del zika que comprende proteinas no estructurales y su uso en una composicion inmunogenica. | |
CL2015001757A1 (es) | Genotipado por fusión de alta resolución del ibv, csfv y ndv |